AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12063371 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin
Number of subjects: 3864
Study 12063371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3864
Study 12063371 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin (among S. aureus carriers)
Number of subjects: 3864
Study 12063371 — intervention group
Group type: COMPARATOR
Intervention: Placebo (among S. aureus carriers)
Number of subjects: 3864
Study 10589634 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine-morphine group (oral clonidine 5 microg/kg + epidural morphine 2 mg)
Number of subjects: 60
Study 10589634 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine-morphine group
Number of subjects: 60
Study 10589634 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine-placebo group
Number of subjects: 60
Study 10589634 — intervention group
Group type: COMPARATOR
Intervention: Placebo-morphine group
Number of subjects: 60
Study 8609105 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute primary repair (Group 1)
Number of subjects: 150
Study 8609105 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute repair with a synthetic ligament-augmentation device (Group 2)
Number of subjects: 150
Study 8609105 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute repair augmented with an autologous bone-patellar ligament-bone graft (Group 3)
Number of subjects: 150
Study 8609105 — intervention group
Group type: COMPARATOR
Intervention: Control Group (non-augmented repair)
Number of subjects: 150
Study 1766054 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT/LCT lipid emulsion
Number of subjects: 18
Study 1766054 — intervention group
Group type: COMPARATOR
Intervention: LCT lipid emulsion
Number of subjects: 18
Study 6870163 — intervention group
Group type: EXPERIMENTAL
Intervention: Layer bandage
Number of subjects: 119
Study 6870163 — intervention group
Group type: COMPARATOR
Intervention: Elastic adhesive tape bandage
Number of subjects: 119
Study 6870163 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonixin 300 mg three times daily
Number of subjects: 119
Study 6870163 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxyphenbutazone 100 mg three times daily
Number of subjects: 119
Study 6870163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 30890132 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus multisensory intervention
Number of subjects: 200
Study 30890132 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 200
Study 28004335 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP intervention (2-years, telephonic, primary care staff)
Number of subjects: 257
Study 28004335 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived educator support
Number of subjects: 257
Study 28004335 — intervention group
Group type: EXPERIMENTAL
Intervention: Support effect on weight loss
Number of subjects: 257
Study 27354118 — intervention group
Group type: EXPERIMENTAL
Intervention: QAW039 (500 mg once daily)
Number of subjects: 170
Study 27354118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 25117033 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy plus education (Group 1)
Number of subjects: 30
Study 25117033 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy plus strength training (Group 2)
Number of subjects: 30
Study 25117033 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy (Control)
Number of subjects: 30
Study 21779093 — intervention group
Group type: COMPARATOR
Intervention: Low volume (LV) alginate preload (9.9 g alginate in 330 ml)
Number of subjects: 20
Study 21779093 — intervention group
Group type: COMPARATOR
Intervention: High volume (HV) alginate preload (15.0 g alginate in 500 ml)
Number of subjects: 20
Study 21779093 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo beverage
Number of subjects: 20
Study 19616172 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 9
Study 19616172 — intervention group
Group type: COMPARATOR
Intervention: Beck Depression Inventory (BDI)‐II
Number of subjects: 9
Study 17724242 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management program provided by advanced practice nurses for 8 weeks after discharge
Number of subjects: 335
Study 17724242 — intervention group
Group type: COMPARATOR
Intervention: Usual care system (Control group)
Number of subjects: 335
Study 16251566 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermodilution cardiac output (TD-CO)
Number of subjects: 58
Study 16251566 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal Doppler cardiac output (ED-CO)
Number of subjects: 58
Study 12211496 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular dose aspirin (325 mg)
Number of subjects: 46
Study 12211496 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 mg)
Number of subjects: 46
Study 12211496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 11482124 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited Medicare community care service benefit and case management
Number of subjects: 0
Study 11482124 — intervention group
Group type: COMPARATOR
Intervention: Regular medical care (control group)
Number of subjects: 0
Study 8949670 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol 320 mgI ml‐1 (Visipaque)
Number of subjects: 100
Study 8949670 — intervention group
Group type: COMPARATOR
Intervention: Iohexol 350 mgI ml‐1 (Omnipaque)
Number of subjects: 100
Study 8949670 — intervention group
Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 100
Study 8949670 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 100
Study 8949670 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol (60-100 ml)
Number of subjects: 100
Study 8949670 — intervention group
Group type: COMPARATOR
Intervention: Iohexol (60-100 ml)
Number of subjects: 100
Study 8949670 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol and Iohexol
Number of subjects: 100
Study 1827340 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural sufentanil (ES)
Number of subjects: 31
Study 1827340 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (IS)
Number of subjects: 31
Study 1827340 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sufentanil (IVS)
Number of subjects: 31
Study 6452825 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonabsorbable multifilament suture material
Number of subjects: 161
Study 6452825 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonabsorbable monofilament suture material
Number of subjects: 161
Study 6452825 — intervention group
Group type: EXPERIMENTAL
Intervention: Long‐term absorbable suture material
Number of subjects: 161
Study 6452825 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonabsorbable multifilament and monofilament suture materials)
Number of subjects: 161
Study 30913051 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.01%
Number of subjects: 40
Study 30913051 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 40
Study 27964912 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb massage (2-minute massage before venipuncture)
Number of subjects: 80
Study 26009712 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg tablets thrice daily for 7 days
Number of subjects: 24
Study 26009712 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (cetirizine 10 mg OD and calamine)
Number of subjects: 24
Study 23841586 — intervention group
Group type: EXPERIMENTAL
Intervention: Video education and information leaflets
Number of subjects: 61
Study 23841586 — intervention group
Group type: COMPARATOR
Intervention: Information leaflets alone
Number of subjects: 61
Study 21999640 — intervention group
Group type: EXPERIMENTAL
Intervention: Technosphere inhaled insulin + insulin glargine (TI+G)
Number of subjects: 618
Study 21999640 — intervention group
Group type: COMPARATOR
Intervention: Premixed aspart insulin 70/30
Number of subjects: 618
Study 19735497 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDCAP (treatment, E)
Number of subjects: 107
Study 16443446 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading for translation
Number of subjects: 0
Study 16443446 — intervention group
Group type: COMPARATOR
Intervention: Reading for repetition
Number of subjects: 0
Study 12606844 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupenthixol (mean daily dose 6.6 mg/day)
Number of subjects: 0
Study 12606844 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (mean daily dose 3.6 mg/day)
Number of subjects: 0
Study 10669447 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalthea Project
Number of subjects: 161
Study 10669447 — intervention group
Group type: COMPARATOR
Intervention: General practitioner care
Number of subjects: 161
Study 10173126 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate 200 mg
Number of subjects: 0
Study 10173126 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg
Number of subjects: 0
Study 10173126 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate 200 mg (type IIa)
Number of subjects: 0
Study 10173126 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg (type IIa)
Number of subjects: 0
Study 10173126 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate 200 mg (type IIb)
Number of subjects: 0
Study 10173126 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg (type IIb)
Number of subjects: 0
Study 8453546 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorus-32 as primary adjuvant treatment
Number of subjects: 313
Study 8453546 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorus-32 as consolidating therapy after second-look surgery
Number of subjects: 313
Study 8453546 — intervention group
Group type: COMPARATOR
Intervention: Phosphorus-32 (randomized group)
Number of subjects: 313
Study 8453546 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorus-32 treatment
Number of subjects: 313
Study 8453546 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorus-32 scintigraphy
Number of subjects: 313
Study 2937598 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 to 160 mg twice a day)
Number of subjects: 19
Study 2937598 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (5 to 20 mg twice a day)
Number of subjects: 19
Study 30227833 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary and physical activity lifestyle intervention
Number of subjects: 1555
Study 26689302 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized feedback interventions (PFIs)
Number of subjects: 212
Study 26689302 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (control group)
Number of subjects: 212
Study 24516038 — intervention group
Group type: EXPERIMENTAL
Intervention: octreotide LAR 30 mg intramuscularly every 4 weeks
Number of subjects: 139
Study 24516038 — intervention group
Group type: COMPARATOR
Intervention: Physician's treatment of choice in case of diarrhea
Number of subjects: 139
Study 22310472 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein content formula (HP)
Number of subjects: 41
Study 22310472 — intervention group
Group type: COMPARATOR
Intervention: Lower protein content formula (LP)
Number of subjects: 41
Study 19579144 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolling-over maneuver (ROM)
Number of subjects: 22
Study 19579144 — intervention group
Group type: COMPARATOR
Intervention: Canalith repositioning maneuver (CRP)
Number of subjects: 22
Study 18827176 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/day (titrated to 10 mg if BP goal not achieved)
Number of subjects: 411
Study 18827176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411
Study 16179197 — intervention group
Group type: EXPERIMENTAL
Intervention: sEMG and 3-D motion analysis systems
Number of subjects: 46
Study 16179197 — intervention group
Group type: COMPARATOR
Intervention: Control group (asymptomatic male subjects)
Number of subjects: 46
Study 12525531 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 375
Study 12525531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study 11392163 — intervention group
Group type: EXPERIMENTAL
Intervention: OAT-omeprazole (2 x 20 mg), amoxycillin (2 x 1000 mg), tinidazole (2 x 500 mg)
Number of subjects: 142
Study 11392163 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC-omeprazole (2 x 20 mg), amoxycillin (2 x 1000 mg), clarithromycin (2 x 250 mg)
Number of subjects: 142
Study 11392163 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC group (smokers)
Number of subjects: 142
Study 11392163 — intervention group
Group type: EXPERIMENTAL
Intervention: OAT group (drinkers)
Number of subjects: 142
Study 11392163 — intervention group
Group type: EXPERIMENTAL
Intervention: OAT group (non-drinkers)
Number of subjects: 142
Study 11392163 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC group (non-drinkers)
Number of subjects: 142
Study 11392163 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis (OAT + OAC)
Number of subjects: 142
Study 8842111 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteflene (25 mg/kg)
Number of subjects: 41
Study 8842111 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine (15 mg/kg)
Number of subjects: 41
Study 8842111 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteflene
Number of subjects: 41
Study 8842111 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine
Number of subjects: 41
Study 1503438 — intervention group
Group type: COMPARATOR
Intervention: S-1108 (200 mg TID for 8 days)
Number of subjects: 0
Study 6147640 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAP-5
Number of subjects: 186
Study 6147640 — intervention group
Group type: COMPARATOR
Intervention: Hexa-CAF
Number of subjects: 186
Study 29799960 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg (weeks 0 and 4, then every 8 weeks)
Number of subjects: 1829
Study 29799960 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg
Number of subjects: 1829
Study 29799960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1829
Study 29799960 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (80 mg week 0, 40 mg week 1, then every 2 weeks)
Number of subjects: 1829
Study 29799960 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 1829
Study 26884585 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib 850 mg once daily
Number of subjects: 267
Study 26884585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 24397690 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm exercise during cold water immersion at 15°C (CW15+AE)
Number of subjects: 8
Study 24397690 — intervention group
Group type: COMPARATOR
Intervention: Cold water immersion at 15°C (CW15)
Number of subjects: 8
Study 24397690 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm exercise during thermoneutral immersion at 34°C (TW34+AE)
Number of subjects: 8
Study 24397690 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-immersed arm exercise (AE)
Number of subjects: 8
Study 22356732 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathe Easier Online (BEO)
Number of subjects: 42
Study 22356732 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 42
Study 20831723 — intervention group
Group type: EXPERIMENTAL
Intervention: Trail-walking exercise (TWE) program
Number of subjects: 60
Study 20831723 — intervention group
Group type: COMPARATOR
Intervention: Walking (W) group
Number of subjects: 60
Study 18669959 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted navigation
Number of subjects: 80
Study 18669959 — intervention group
Group type: COMPARATOR
Intervention: Conventional total knee replacement
Number of subjects: 80
Study 15989829 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation techniques (RT) combined with conventional treatment
Number of subjects: 104
Study 15989829 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 104
Study 12466335 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg androstenedione
Number of subjects: 30
Study 12466335 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg androstenedione
Number of subjects: 30
Study 12466335 — intervention group
Group type: COMPARATOR
Intervention: Control (0 mg androstenedione)
Number of subjects: 30
Study 10466913 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhesus‐human reassortant rotavirus tetravalent vaccine (RRV‐TV)
Number of subjects: 0
Study 8554942 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg)
Number of subjects: 8
Study 8554942 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g kg‐1)
Number of subjects: 8
Study 8554942 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g kg‐1) + Caffeine (400 mg)
Number of subjects: 8
Study 8554942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1939687 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimeprazine tartrate (sedative medication) prescribed in a reducing dose over the first 10 days of extinction
Number of subjects: 0
Study 1939687 — intervention group
Group type: COMPARATOR
Intervention: Extinction alone
Number of subjects: 0
Study 1939687 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered double-blind
Number of subjects: 0
Study 7006381 — intervention group
Group type: EXPERIMENTAL
Intervention: Methicillin sodium
Number of subjects: 149
Study 7006381 — intervention group
Group type: COMPARATOR
Intervention: Nafcillin sodium
Number of subjects: 149
Study 7006381 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 149
Study 31988384 — intervention group
Group type: EXPERIMENTAL
Intervention: Ai Chi
Number of subjects: 20
Study 31988384 — intervention group
Group type: COMPARATOR
Intervention: Conventional water-based exercise
Number of subjects: 20
Study 30322794 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia During Hospitalization (HyDHo) scoring system
Number of subjects: 300
Study 30322794 — intervention group
Group type: EXPERIMENTAL
Intervention: HyDHo scoring system with a score of ≥9
Number of subjects: 300
Study 30322794 — intervention group
Group type: EXPERIMENTAL
Intervention: HyDHo scoring system
Number of subjects: 300
Study 28648803 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg twice-daily)
Number of subjects: 313
Study 28648803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 28648803 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 313
Study 25078717 — intervention group
Group type: EXPERIMENTAL
Intervention: Real occipital transcutaneous electrical stimulation (OTES)
Number of subjects: 160
Study 25078717 — intervention group
Group type: COMPARATOR
Intervention: Sham occipital transcutaneous electrical stimulation (OTES)
Number of subjects: 160
Study 24177376 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir plus peginterferon and ribavirin
Number of subjects: 0
Study 24177376 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon and ribavirin
Number of subjects: 0
Study 21184620 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Number of subjects: 101
Study 21184620 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Number of subjects: 101
Study 21184620 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 600 μg
Number of subjects: 101
Study 21184620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 18388156 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 18388156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18388156 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus methotrexate
Number of subjects: 0
Study 18388156 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate
Number of subjects: 0
Study 17579541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 90
Study 17579541 — intervention group
Group type: COMPARATOR
Intervention: Befriending (Control)
Number of subjects: 90
Study 15163137 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced communication with direct-to-member postcards
Number of subjects: 1930
Study 15163137 — intervention group
Group type: COMPARATOR
Intervention: Standard contract changes
Number of subjects: 1930
Study 11460023 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoxynol-9 gel (52.5 mg)
Number of subjects: 278
Study 11460023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 11020194 — intervention group
Group type: EXPERIMENTAL
Intervention: Height of 10 m 22 cm with eyes open and closed (acrophobic group)
Number of subjects: 30
Study 11020194 — intervention group
Group type: COMPARATOR
Intervention: Height of 1 m and 2 m with eyes open and closed
Number of subjects: 30
Study 11020194 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided to the roof with eyes closed
Number of subjects: 30
Study 11020194 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes open after eyes closed measurement
Number of subjects: 30
Study 10423625 — intervention group
Group type: EXPERIMENTAL
Intervention: edrophonium (1 mg/kg) and atropine (0.01 mg/kg) reversal (E/A)
Number of subjects: 30
Study 10423625 — intervention group
Group type: COMPARATOR
Intervention: placebo (P)
Number of subjects: 30
Study 8475472 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 0
Study 8475472 — intervention group
Group type: COMPARATOR
Intervention: Control (without acamprosate)
Number of subjects: 0
Study 3860788 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin F2 alpha (16 mg diluted in 40 mL of saline)
Number of subjects: 102
Study 3860788 — intervention group
Group type: COMPARATOR
Intervention: Saline only (control)
Number of subjects: 102
Study 30318916 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression Stockings (CS)
Number of subjects: 20
Study 30318916 — intervention group
Group type: COMPARATOR
Intervention: Control (regular socks)
Number of subjects: 20
Study 30098513 — intervention group
Group type: EXPERIMENTAL
Intervention: Hostile marital interactions
Number of subjects: 86